Comparison between sodium–glucose cotransporter 2 inhibitors and pioglitazone as additions to insulin therapy in type 2 diabetes patients: A systematic review with an indirect comparison meta‐analysis

• Published in: Journal of diabetes investigation Vol. 9; no. 4; pp. 882 - 892
• Main Authors: Cho, Yun Kyung, Kim, Ye‐Jee, Kang, Yu Mi, Lee, Seung Eun, Park, Joong‐Yeol, Lee, Woo Je, Jung, Chang Hee
• Format: Journal Article
• Language: English
• Published: Japan John Wiley & Sons, Inc 01.07.2018; John Wiley and Sons Inc
• Subjects: Aged; Clinical trials; Diabetes; Diabetes mellitus; Diabetes mellitus (non-insulin dependent); Diabetes Mellitus, Type 2 - drug therapy; Drug Therapy, Combination; Female; Glucose; Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents - therapeutic use; Insulin; Insulin - therapeutic use; Male; Meta-analysis; Middle Aged; Na+/glucose cotransporter; Original; PCB; Pioglitazone; Polychlorinated biphenyls; Randomized Controlled Trials as Topic; Sodium; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sodium–glucose cotransporter 2 inhibitors; Thiazolidinediones - therapeutic use; Treatment Outcome; Sodium-glucose cotransporter 2 inhibitors; Pioglitazone; Meta-analysis

Aims/Introduction We aimed to evaluate the efficacy and safety of pioglitazone (PIO) and sodium–glucose cotransporter 2 inhibitors (SGLT2i) as additions to insulin therapy for the management of type 2 diabetes mellitus. Materials and Methods We searched PubMed, EMBASE, the Cochrane Central Register...